WuXi AppTec Acquires HD Biosciences, a Biologics CRO

WuXi AppTec, China's largest CRO/CMO, has acquired Shanghai's HD Biosciences. Founded in 2002, HD Bio is a pre-clinical CRO that specializes in biologic drug discovery. WuXi said HD Bio will strengthen its biologics R&D capability from target validation to lead discovery and optimization. In 2016, HD Bio opened an expanded lab in Shanghai's Zhangjiang Hi-Tec Park, and it has a US lab in San Diego. WuXi's newest subsidiary will continue to add services after the acquisition. The financial details of the acquisition were not disclosed. More details.... Share this with colleagues: // //